☆ 4.7 Meeting Abstract

Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib

EUROPEAN JOURNAL OF CANCER (2014)

Get Full Text
Add to Collection

Journal

EUROPEAN JOURNAL OF CANCER
Volume 50, Issue -, Pages 8-8

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/S0959-8049(14)70131-5

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.